Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

SELLAS Life Sciences (SLS) EBT (2020 - 2024)

SELLAS Life Sciences (SLS) has disclosed EBT for 8 consecutive years, with -$6.7 million as the latest value for Q4 2024.

  • Quarterly EBT rose 17.2% to -$6.7 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$30.9 million through Dec 2024, up 17.71% year-over-year, with the annual reading at -$26.9 million for FY2025, 13.01% up from the prior year.
  • EBT for Q4 2024 was -$6.7 million at SELLAS Life Sciences, up from -$7.1 million in the prior quarter.
  • The five-year high for EBT was -$2.2 million in Q1 2021, with the low at -$16.7 million in Q1 2022.
  • Average EBT over 5 years is -$7.6 million, with a median of -$7.3 million recorded in 2022.
  • The sharpest move saw EBT surged 44.76% in 2021, then plummeted 645.43% in 2022.
  • Over 5 years, EBT stood at -$4.2 million in 2020, then tumbled by 179.37% to -$11.6 million in 2021, then increased by 18.7% to -$9.4 million in 2022, then increased by 13.87% to -$8.1 million in 2023, then rose by 17.2% to -$6.7 million in 2024.
  • According to Business Quant data, EBT over the past three periods came in at -$6.7 million, -$7.1 million, and -$7.5 million for Q4 2024, Q3 2024, and Q2 2024 respectively.